Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4076 Following Multiple Ascending Dose Administration to T2DM Subjects With Non-Alcoholic Fatty Liver Disease
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 24 Nov 2017
At a glance
- Drugs RG 125 (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 21 Nov 2017 Planned End Date changed from 12 Dec 2017 to 30 Nov 2018.
- 21 Nov 2017 Planned primary completion date changed from 12 Dec 2017 to 30 Nov 2018.
- 23 Aug 2017 Planned End Date changed from 21 Dec 2017 to 12 Dec 2017.